Literature DB >> 30902385

Norrin maintains malignancy of gastric cancer cells in part through activating AKT signaling.

Lei Liu1, Zhong-Yi Qin1, Qin Liu1, Liang-Zhi Wen1, Ke-Wei Liu1, Yan Guo1, Yin-Bin Zhou1, Bin Wang1, Dong-Feng Chen2, Tao Wang3.   

Abstract

Human tumorigenesis resembles embryogenesis by aberrant activation of several developmental pathways including Wnt/β-catenin signaling. Norrin is an atypical ligand for Frizzled receptor that is preferentially expressed in the endothelium to promote retinal vascularization during development. However, its expression pattern and potential roles in human cancers remain unclear. Here we report that Norrin expression is elevated in the parenchymal cells, but not endothelial cells, in gastric cancer (GC). Moreover, Norrin is required for growth and invasion of GC cells and its expression status is associated with unfavorable outcomes. However, analysis of the TGCA database demonstrates that Norrin expression status is not correlated with key target genes of Wnt/β-catenin signaling. Among several signaling pathways hyperactivated in cancer, Norrin-depleted GC cells also display down-regulated AKT signaling except the canonical Wnt/β-catenin signaling. Consistently, small molecule-induced cytosolic activation of AKT partially rescues the proliferative and invasive capability of Norrin-depleted cells. Together, these findings suggest a novel role of Norrin in gastric tumorigenesis that could be exploited for adjuvant therapy against the deadly malignancy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKT signaling; Gastric cancer; Norrin; Wnt/β-catenin signaling

Mesh:

Substances:

Year:  2019        PMID: 30902385     DOI: 10.1016/j.bbrc.2019.03.044

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  IRF-1 Inhibits Angiogenic Activity of HPV16 E6 Oncoprotein in Cervical Cancer.

Authors:  Seung Bae Rho; Seung-Hoon Lee; Hyun-Jung Byun; Boh-Ram Kim; Chang Hoon Lee
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.